KR100371008B1 - Manufacturing method of transfer paper for coating - Google Patents

Manufacturing method of transfer paper for coating Download PDF

Info

Publication number
KR100371008B1
KR100371008B1 KR10-2000-0045491A KR20000045491A KR100371008B1 KR 100371008 B1 KR100371008 B1 KR 100371008B1 KR 20000045491 A KR20000045491 A KR 20000045491A KR 100371008 B1 KR100371008 B1 KR 100371008B1
Authority
KR
South Korea
Prior art keywords
stent
glass tube
leopro
torr
desiccator
Prior art date
Application number
KR10-2000-0045491A
Other languages
Korean (ko)
Other versions
KR20020012063A (en
Inventor
정명호
장양수
조동련
Original Assignee
조동련
장양수
정명호
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 조동련, 장양수, 정명호 filed Critical 조동련
Priority to KR10-2000-0045491A priority Critical patent/KR100371008B1/en
Publication of KR20020012063A publication Critical patent/KR20020012063A/en
Application granted granted Critical
Publication of KR100371008B1 publication Critical patent/KR100371008B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/0005—Use of materials characterised by their function or physical properties
    • A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
    • A61L33/0041—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate characterised by the choice of an antithrombatic agent other than heparin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/0077—Special surfaces of prostheses, e.g. for improving ingrowth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06—Blood vessels
    • A61F2/07—Stent-grafts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/02—Inorganic materials
    • A61L31/022—Metals or alloys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/0005—Use of materials characterised by their function or physical properties
    • A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D3/00—Pretreatment of surfaces to which liquids or other fluent materials are to be applied; After-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials
    • B05D3/14—Pretreatment of surfaces to which liquids or other fluent materials are to be applied; After-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials by electrical means
    • B05D3/141—Plasma treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2420/00—Materials or methods for coatings medical devices
    • A61L2420/04—Coatings containing a composite material such as inorganic/organic, i.e. material comprising different phases

Abstract

본 발명은 인체 혈관의 협착된 부위를 확장시키도록 한 스텐트와 제조 방법에 관한 것으로, 특히 스텐트의 표면에 혈소판 응집 억제제가 피복되도록 함으로써, 시술 후에 혈관의 재협착을 방지하도록 한 혈소판 응집 억제제가 피복된 스텐트의 제조방법에 관한 것이다.The present invention relates to a stent and a manufacturing method for expanding the constricted portion of the human blood vessels, in particular to the platelet aggregation inhibitor is coated on the surface of the stent, the platelet aggregation inhibitor to prevent the restenosis of blood vessels after the procedure It relates to a method for producing a stent.

본 발명은 혈관 확장 시술에 사용되는 스텐트를 제조하는 방법에 있어서,The present invention provides a method for producing a stent used in the vasodilation procedure,

파이렉스(Pyrex) 유리관으로 제작한 관형 반응기(Tubular reactor)에 스텐트를 고정한 후, 진공 펌프로 압력을 30 m torr 이하까지 낮추고, 스텐트 표면에 아민기를 도입하기 위하여 Diaminocyclohexane (DACH) monomer를 일정 유량 (25 m torr)으로 반응기 내로 도입하여 RF power generator로 플라스마를 발생시키도록 한 스텐트 표면개질 공정과;After fixing the stent in a tubular reactor made of Pyrex glass tube, the pressure was lowered to 30 m torr or less with a vacuum pump, and a dihydrocyclohexane (DACH) monomer was introduced at a constant flow rate to introduce an amine group to the surface of the stent. m torr) and a stent surface modification process introduced into the reactor to generate plasma with an RF power generator;

유리관에 주사기로 레오프로 주사액 2 ml를 넣고 처리된 스텐트를 침지시켜, 스텐트에 도입된 아민기에 레오프로의 카르복실기(COOH)를 공유결합 시킴으로써, 스텐트와 레오프로의 접착력을 향상시키도록 한 피복 공정과;The coating process was performed by adding 2 ml of the injection solution into the glass tube with a syringe into a glass tube and immersing the treated stent, thereby covalently bonding the carboxyl group (COOH) of the leopro to the amine group introduced into the stent, thereby improving the adhesion between the stent and the leopro. ;

데시케이터에서 약 24시간 이상 실시하고, 건조 과정에서 생길 수 있는 오염을 방지하도록 청결을 유지하여 데시케이터에서 약 24기산 이상 건조시키도록 한 건조 공정으로;A drying process carried out in the desiccator for at least about 24 hours and kept clean so as to prevent contamination that may occur during the drying process and dried in the desiccator for at least about 24 acids;

구성되는 것을 특징으로 한다.It is characterized in that the configuration.

Description

혈소판 응집 억제제 부착 스텐트의 그 제조 방법 { Manufacturing method of transfer paper for coating }Manufacturing method of platelet aggregation inhibitor adherent stents {Manufacturing method of transfer paper for coating}

본 발명은 인체 혈관의 협착된 부위를 확장시키도록 한 스텐트와 제조 방법에 관한 것으로, 특히 스텐트의 표면에 혈소판 응집 억제제가 피복되도록 함으로써, 시술 후에 혈관의 재협착을 방지하도록 한 혈소판 응집 억제제가 피복된 스텐트의 제조방법에 관한 것이다.The present invention relates to a stent and a manufacturing method for expanding the constricted portion of the human blood vessels, in particular to the platelet aggregation inhibitor is coated on the surface of the stent, the platelet aggregation inhibitor to prevent the restenosis of blood vessels after the procedure It relates to a method for producing a stent.

일반적으로 인체의 혈관에 콜레스테롤 침적 등으로 인하여 관상동맥, 말초혈관 등의 인체 내 혈관의 협착이 발생하여, 혈류의 흐름이 저하되거나 이로 인하여협심증 환자의 경우에 심한 통증이나 급작스런 사망의 원인이 되기도 한다.In general, blood vessel narrowing of coronary arteries and peripheral blood vessels occurs due to cholesterol deposition in the blood vessels of the human body, and the flow of blood is reduced or this may cause severe pain or sudden death in patients with angina pectoris. .

이러한 인체 내 혈관의 협착을 치료하기 위하여 다양한 방법이 제시되고 있었으며, 근래 들어 특히, 인체를 개복하는 시술없이, 스텐트(stent)와 풍선 카테터 (balloon catheter)를 이용하여, 인체 혈관의 협착 부위를 확장시키는 시술 방법이 발전되고 있는 추세이다.Various methods have been proposed to treat the narrowing of blood vessels in the human body, and in recent years, a stent and balloon catheter have been used to expand the narrowing region of the human blood vessels, especially without the procedure of opening the human body. It is a trend that the method of treatment is being developed.

상기한 스텐트와 풍선 카테터를 이용한 혈관 확장 시술 방법은, 풍선 카테터 말단의 팽창부에 스텐트를 장착하고, 혈관 내의 협착 부위에서 기압으로 팽창부가 팽창함에 따라, 장착된 스텐트가 팽창되어 혈관 내의 협착 부위를 확장시키도록 하였다.In the method of vasodilation using the stent and balloon catheter, the stent is attached to the inflation portion of the balloon catheter end, and as the inflation portion expands at atmospheric pressure from the constriction portion in the blood vessel, the mounted stent expands to expand the constriction portion in the blood vessel. To expand.

그러나, 상기한 종래의 스텐트를 이용한 혈관을 확장하는 시술 방법은, 시술 후에 시술 부위 혈관의 재협착 발생율이 70 % 이상으로 높게 나타나는 문제점이 있었다.However, the conventional method for expanding blood vessels using the stent has a problem in that the incidence of restenosis of the blood vessels at the treatment site is higher than 70% after the procedure.

의료계에서 상기한 혈관 확장 시술 후에, 혈관의 재협착율을 감소시킬 수 있는 안정된 혈관 확장 시술 방법과 의료 기구에 대한 연구와 개발이 절실하게 요구되고 있는 실정이었다.After the vasodilation procedure in the medical field, research and development of a stable vasodilation method and a medical device that can reduce the restenosis rate of blood vessels are urgently needed.

따라서, 상기한 문제점을 해결하기 위한 본 발명은, 스텐트의 표면에 혈소판 이 응집되는 것을 억제, 차단할 수 있도록 한 응집 억제제가 부착, 피복되도록 되도록 처리함으로써, 카테터에 의한 혈관 확장 시술 후에, 스텐트 표면에 피복된 혈소판 응집 억제제의 작용으로, 혈관의 시술 부위에 혈소판이 응집되는 것을 방지하기 때문에, 혈관의 재협착율을 현저하게 감소시킬 수 있도록 하는데 그 목적이 있는 것이다.Therefore, the present invention for solving the above problems, by treating the plate to prevent the aggregation of the platelet to prevent the aggregation of the platelet is attached to, the coating to prevent the coagulation, by the catheter vasodilation treatment, after the stent surface The purpose of the coated platelet aggregation inhibitor is to prevent the aggregation of platelets at the site of blood vessel treatment, thereby significantly reducing the rate of restenosis of blood vessels.

도 1은 본 발명의 혈소판 응집 억제제가 피복된 스텐트를 30 배 확대한 사진1 is a 30-fold enlarged photograph of a stent coated with platelet aggregation inhibitor of the present invention

도 2는 본 발명의 혈소판 응집 억제제가 피복된 스텐트를 2000배 확대한 사진Figure 2 is a photograph of a 2000 times magnification of the stent coated with platelet aggregation inhibitor of the present invention

도면의 주요부분에 대한 부호의 설명Explanation of symbols for main parts of the drawings

S : 스텐트 표면개질 공 c : 피복 공정S: Stent surface modification ball c: Coating process

D : 건조 공정D: drying process

본 발명은 혈관 확장 시술에 사용되는 스텐트를 제조하는 방법에 있어서,The present invention provides a method for producing a stent used in the vasodilation procedure,

파이렉스(Pyrex) 유리관으로 제작한 관형 반응기(Tubular reactor)에 스텐트를 고정한 후, 진공 펌프로 압력을 30 m torr 이하까지 낮추고, 스텐트 표면에 아민기를 도입하기 위하여 Diaminocyclohexane (DACH) monomer를 일정 유량 (25 m torr)으로 반응기 내로 도입하여 RF power generator로 플라스마를 발생시키도록 한 스텐트 표면개질 공정과;After fixing the stent in a tubular reactor made of Pyrex glass tube, the pressure was lowered to 30 m torr or less with a vacuum pump, and a dihydrocyclohexane (DACH) monomer was introduced at a constant flow rate to introduce an amine group to the surface of the stent. m torr) and a stent surface modification process introduced into the reactor to generate plasma with an RF power generator;

유리관에 주사기로 레오프로 주사액 2 ml를 넣고 처리된 스텐트를 침지시켜, 스텐트에 도입된 아민기에 레오프로의 카르복실기(COOH)를 공유결합 시킴으로써, 스텐트와 레오프로의 접착력을 향상시키도록 한 피복 공정과;The coating process was performed by adding 2 ml of the injection solution into the glass tube with a syringe into a glass tube and immersing the treated stent, thereby covalently bonding the carboxyl group (COOH) of the leopro to the amine group introduced into the stent, thereby improving the adhesion between the stent and the leopro. ;

데시케이터에서 약 24시간 이상 실시하고, 건조 과정에서 생길 수 있는 오염을 방지하도록 청결을 유지하여 데시케이터에서 약 24기산 이상 건조시키도록 한 건조 공정으로;A drying process carried out in the desiccator for at least about 24 hours and kept clean so as to prevent contamination that may occur during the drying process and dried in the desiccator for at least about 24 acids;

구성되는 것을 특징으로 한다.It is characterized in that the configuration.

도 1은 본 발명의 혈소판 응집 억제제가 피복된 스텐트를 30 배 확대한 사진이고, 도 2는 본 발명의 혈소판 응집 억제제가 피복된 스텐트를 2000배 확대한 사진이다.1 is a 30 times magnification of a stent coated platelet aggregation inhibitor of the present invention, Figure 2 is a 2000 times magnification of a stent coated platelet aggregation inhibitor of the present invention.

이상에서 설명한 바와 같은 본 발명의 구체적인 제조 방법을 공정별로 살펴보면 다음과 같다.Looking at the specific manufacturing method of the present invention as described above for each step as follows.

스텐트 표면개질 공정 (S)Stent Surface Modification Process (S)

스텐레스강이나 니켈-티타늄합금, 플라티나, 탄탈, 백금 등의 금속 소재의 세선을 그물눈 형태로 형성된 관상체인 스텐트에 아민기를 도입하기 위하여 플라스마 중합 반응을 실시한다.Plasma polymerization is performed to introduce an amine group into a stent, which is a tubular body in which thin wires of a metallic material such as stainless steel, nickel-titanium alloy, platinum, tantalum or platinum are formed in a mesh shape.

파이렉스(Pyrex) 유리관으로 제작한 관형 반응기(Tubular reactor)에 스텐트를 고정한 후, 진공 펌프로 압력을 30 m torr 이하까지 낮추고, 스텐트 표면에 아민기를 도입하기 위하여 Diaminocyclohexane (DACH) monomer를 일정 유량 (25 m torr)으로 반응기 내로 도입하여 RF power generator로 플라스마를 발생시킨다.After fixing the stent to a tubular reactor made of Pyrex glass tube, the pressure was lowered to 30 m torr or lower with a vacuum pump, and a dilute flow rate of diaminocyclohexane (DACH) monomer was introduced to introduce an amine group to the surface of the stent (25 m torr) into the reactor to generate plasma with an RF power generator.

플라스마 중합의 power는 20W 3분과 10W 2분 동안 처리하는 것이 바람직하다.The plasma polymerization power is preferably treated for 20 W 3 minutes and 10 W 2 minutes.

피복 공정 (C)Coating Process (C)

물에 5분 동안 넣고 끓인 다음 인큐베이터에서 건조한 유리관에 주사기로 레오프로 주사액 2 ml를 넣고 처리된 스텐트를 침지시켜, 스텐트에 도입된 아민기에 레오프로의 카르복실기(COOH)를 공유결합 시킴으로써, 스텐트와 레오프로의 접착력을 향상시킨다.Simmer for 5 minutes in water, boil and inject 2 ml of Leopro injection into a dry glass tube in an incubator and immerse the treated stent, and covalently bond the carboxyl group (COOH) of the leopro to the amine introduced into the stent. Improve the adhesion of the pro.

상기 반응 시간은 대략 1시간 가량이 적정하며, 반응이 끝난 다음 스텐트를 레오프로로 주사액이 방울지지 않도록 공기를 주입하여 준다.The reaction time is about 1 hour is appropriate, and after the reaction is completed, the air is injected into the stent to prevent the injection solution to drop into the leopro.

혈소판 당단백질 IIb/IIIa 수용체 차단제 중 하나인 Abciximab (ReoPro)은 혈소판에 매우 선택적이며 강력한 항 혈소판작용을 갖는 약물로써, 급성 관상동맥증후군에 효과적으로 사용된다.Abciximab (ReoPro), one of the platelet glycoprotein IIb / IIIa receptor blockers, is a highly selective and potent antiplatelet agent for platelets and is effectively used for acute coronary syndrome.

건조 공정 (D)Drying Process (D)

건조는 데시케이터에서 약 24시간 이상 실시하고, 건조 과정에서 생길 수 있는 오염을 방지하기 위하여 청결을 유지하는 것이 바람직하다.Drying is carried out in a desiccator for at least about 24 hours, and it is desirable to maintain cleanliness to prevent contamination that may occur during the drying process.

상기와 같은 제조 공정으로 혈소판 당단백질 IIb/IIIa 수용체 차단제를 피복한 스텐트와 종래의 스텐트의 동물 시술 결과를, 아래의 표를 참고로 비교하여 살펴보면 다음과 같다.Animal treatment results of the stent coated with the platelet glycoprotein IIb / IIIa receptor blocker and the conventional stent by the above-described manufacturing process, as compared with reference to the table below as follows.

표table

종래의 스텐트Conventional stent 혈소판 응집 억제제피복 스텐트Platelet aggregation inhibitor coating stent 시술 후 재협착율Restenosis after procedure 약 70%About 70% 60% 이하60% less than 혈관 확장 효과의 지속성Persistence of Vasodilation Effect 중medium 장chapter 혈소판 응집 억제 효과Platelet aggregation inhibitory effect 거의 없음Almost none 우수Great 혈관내의 혈류 상태Blood flow in blood vessels 보통usually 양호Good 타 세포 작용 여부Whether other cells work 없음none 혈관 이완세포 등에작용Action on Vascular Relaxation Cells

이상에서 설명한 바와 같이 본 발명은, 스텐트의 표면에 혈소판이 응집되는 것을 억제, 차단할 수 있도록 한 혈소판 당단백 차단제가 부착, 피복되도록 되도록 처리함으로써, 카테터에 의한 혈관 확장 시술 후에, 스텐트 표면에 피복된 혈소판 응집 억제제의 작용으로, 혈관의 시술 부위에 혈소판이 응집되는 것을 방지하기 때문에, 혈관의 재협착율을 현저하게 감소시키고, 보다 안정된 혈관 확장 시술을 시행할 수 있도록 한 유익한 발명인 것이다.As described above, in the present invention, the platelet glycoprotein blocker which prevents and blocks platelet aggregation on the surface of the stent is treated so that the platelet glycoprotein blocker is attached and coated, and thus the platelet coated on the surface of the stent after the blood vessel dilation procedure by the catheter. Since the action of the aggregation inhibitor prevents platelets from agglomerating at the site of blood vessel treatment, it is a beneficial invention that can significantly reduce the rate of restenosis of blood vessels and perform a more stable vasodilation procedure.

Claims (1)

혈관 확장 시술에 사용되는 스텐트를 제조하는 방법에 있어서,In the method for producing a stent to be used for vasodilation, 파이렉스(Pyrex) 유리관으로 제작한 관형 반응기(Tubular reactor)에 스텐트를 고정한 후, 진공 펌프로 압력을 30 m torr 이하까지 낮추고, 스텐트 표면에 아민기를 도입하기 위하여 Diaminocyclohexane (DACH) monomer를 일정 유량 (25 m torr)으로 반응기 내로 도입하여 RF power generator로 플라스마를 발생시키도록 한 스텐트 표면개질 공정(S)과;After fixing the stent in a tubular reactor made of Pyrex glass tube, the pressure was lowered to 30 m torr or less with a vacuum pump, and a dihydrocyclohexane (DACH) monomer was introduced at a constant flow rate to introduce an amine group to the surface of the stent. m torr) and a stent surface modification process (S) introduced into the reactor to generate plasma with an RF power generator; 유리관에 주사기로 레오프로 주사액 2 ml를 넣고 처리된 스텐트를 침지시켜, 스텐트에 도입된 아민기에 레오프로의 카르복실기(COOH)를 공유결합 시킴으로써, 스텐트와 레오프로의 접착력을 향상시키도록 한 피복 공정(C)과;A coating process in which 2 ml of the injection solution was injected into a glass tube with a syringe and the treated stent was immersed to covalently bond the carboxyl group (COOH) of the leopro to the amine group introduced into the stent, thereby improving the adhesion between the stent and the leopro ( C); 데시케이터에서 약 24시간 이상 실시하고, 건조 과정에서 생길 수 있는 오염을 방지하도록 청결을 유지하여 데시케이터에서 약 24기산 이상 건조시키도록 한 건조 공정(D)으로;A drying step (D) for at least about 24 hours in a desiccator and maintaining cleanliness to prevent contamination that may occur during the drying process and drying at least about 24 bases in the desiccator; 구성되는 것을 특징으로 하는 혈소판 응집 억제제가 피복된 스텐트의 제조 방법.A method for producing a stent coated with platelet aggregation inhibitor, characterized in that consisting of.
KR10-2000-0045491A 2000-08-05 2000-08-05 Manufacturing method of transfer paper for coating KR100371008B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR10-2000-0045491A KR100371008B1 (en) 2000-08-05 2000-08-05 Manufacturing method of transfer paper for coating

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR10-2000-0045491A KR100371008B1 (en) 2000-08-05 2000-08-05 Manufacturing method of transfer paper for coating

Publications (2)

Publication Number Publication Date
KR20020012063A KR20020012063A (en) 2002-02-15
KR100371008B1 true KR100371008B1 (en) 2003-02-06

Family

ID=19681931

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2000-0045491A KR100371008B1 (en) 2000-08-05 2000-08-05 Manufacturing method of transfer paper for coating

Country Status (1)

Country Link
KR (1) KR100371008B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007129779A1 (en) * 2006-05-09 2007-11-15 Industry Foundation Of Chonnam National University The coating process of the stent for reopro
KR100778654B1 (en) 2006-05-09 2007-11-28 전남대학교산학협력단 Alpha-Iipoic acid Coating Method of stent for blood vessel

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100759130B1 (en) * 2005-02-12 2007-09-19 휴메드 주식회사 Stent Coated with Anti-integrin Antibody and Process for Preparing the Same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10309320A (en) * 1997-04-24 1998-11-24 Advanced Cardeovascular Syst Inc Intraevascular stent and method for supplying heparin
KR20000069139A (en) * 1996-11-26 2000-11-25 3-디멘져널 파마슈티칼즈 인코오포레이티드 Aminoguanidines and alkoxyguanidines as protease inhibitors
KR20010068945A (en) * 2000-01-11 2001-07-23 박호군 Biocompatible Metallic Materials Grafted with Sulfonated Poly(Ethylene Oxide) and Preparation Thereof
KR100336508B1 (en) * 1999-03-06 2002-05-15 정명호 Heparin coating way of mac stent for a blood vessel

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000069139A (en) * 1996-11-26 2000-11-25 3-디멘져널 파마슈티칼즈 인코오포레이티드 Aminoguanidines and alkoxyguanidines as protease inhibitors
JPH10309320A (en) * 1997-04-24 1998-11-24 Advanced Cardeovascular Syst Inc Intraevascular stent and method for supplying heparin
KR100336508B1 (en) * 1999-03-06 2002-05-15 정명호 Heparin coating way of mac stent for a blood vessel
KR20010068945A (en) * 2000-01-11 2001-07-23 박호군 Biocompatible Metallic Materials Grafted with Sulfonated Poly(Ethylene Oxide) and Preparation Thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007129779A1 (en) * 2006-05-09 2007-11-15 Industry Foundation Of Chonnam National University The coating process of the stent for reopro
KR100778656B1 (en) 2006-05-09 2007-11-28 전남대학교산학협력단 Reopro coating Method of stent for blood vessel
KR100778654B1 (en) 2006-05-09 2007-11-28 전남대학교산학협력단 Alpha-Iipoic acid Coating Method of stent for blood vessel

Also Published As

Publication number Publication date
KR20020012063A (en) 2002-02-15

Similar Documents

Publication Publication Date Title
US6033582A (en) Surface modification of medical implants
CN101199873B (en) Medicament elution instrument nanometer class colon washer machineole drug releasing structure and preparing method thereof
US6245104B1 (en) Method of fabricating a biocompatible stent
WO1996007444A1 (en) Method of making fibrin coated substrates
JPH08505788A (en) Products with weakened and controlled surface binding of biologically active molecules and methods therefor
US6692834B1 (en) Method for coating implantable devices
KR100947094B1 (en) Stent for medical use and manufacturing method thereof
JP2014531933A (en) Intervention medical device and manufacturing method thereof
CN1569270B (en) Method for preparing cardiovascular drug eluting stent
IL175287A (en) Method for preparing drug eluting medical devices and devices obtained therefrom
CN114159197A (en) Degradable biomedical magnesium alloy drug-eluting intravascular stent and preparation method thereof
KR100371008B1 (en) Manufacturing method of transfer paper for coating
CN113069597B (en) Method for preparing titanium dioxide doped ceramic film by sol-gel method
CN202821735U (en) Living beings absorbable medical equipment component
JPH10151190A (en) Stent
JP2022508521A (en) Medical equipment
US11208720B2 (en) Method for treatment medical devices made from nickel-titanium (NiTi) alloys
CN115137879B (en) Blood contact material for resisting coagulation and promoting vascular repair and preparation method thereof
EP3429651B1 (en) Anti-fouling and/or anti-thrombotic medical devices
CN110292665A (en) A kind of composite coating and preparation method thereof of the corrosion-resistant anti-oxidant anti-inflammatory of Mg alloy surface
KR100336508B1 (en) Heparin coating way of mac stent for a blood vessel
KR100778654B1 (en) Alpha-Iipoic acid Coating Method of stent for blood vessel
KR100778656B1 (en) Reopro coating Method of stent for blood vessel
CN101607097B (en) Biological polypeptide medical device and manufacturing method thereof
US20100316787A1 (en) Biomimetic Coating Method

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20090122

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee